KBC Group NV Has $2.38 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

KBC Group NV lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2,047.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 60,514 shares of the company's stock after buying an additional 57,696 shares during the period. KBC Group NV owned 0.07% of CRISPR Therapeutics worth $2,382,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. State Street Corp boosted its stake in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after acquiring an additional 599,304 shares during the last quarter. FMR LLC increased its position in CRISPR Therapeutics by 1.0% in the third quarter. FMR LLC now owns 2,376,166 shares of the company's stock worth $111,632,000 after buying an additional 23,075 shares during the period. Geode Capital Management LLC lifted its stake in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock valued at $47,383,000 after buying an additional 35,196 shares during the last quarter. Baker BROS. Advisors LP boosted its holdings in shares of CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock valued at $39,608,000 after acquiring an additional 743,075 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of CRISPR Therapeutics by 0.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company's stock worth $34,025,000 after acquiring an additional 6,635 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Stock Up 4.3 %

Shares of NASDAQ CRSP traded up $1.73 during mid-day trading on Wednesday, hitting $42.22. 1,838,041 shares of the company traded hands, compared to its average volume of 1,961,911. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of -14.92 and a beta of 1.67. The business has a 50 day moving average of $43.20 and a two-hundred day moving average of $46.82.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million during the quarter, compared to analysts' expectations of $6.65 million. During the same period last year, the company posted ($1.41) earnings per share. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.1 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on CRSP shares. Royal Bank of Canada reissued a "sector perform" rating and set a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. JMP Securities reiterated a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Needham & Company LLC restated a "buy" rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th. Chardan Capital reiterated a "buy" rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Finally, StockNews.com raised CRISPR Therapeutics to a "sell" rating in a report on Monday, December 30th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $77.59.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares of the company's stock, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.